PMGC Holdings (ELAB) Non Operating Income (2022 - 2026)

PMGC Holdings (ELAB) posted Non Operating Income of -$50080.0 for Q1 2026, up 56.19% sequentially from -$114304.0 in Q4 2025.

PMGC Holdings (ELAB) Non Operating Income (2022 - 2026) Analysis & Trends

PMGC Holdings has reported Non Operating Income for 4 years, with the latest figure at -$50080.0 in Q1 2026.

Quarterly Non Operating Income changed N/A year-over-year to -$50080.0 in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $1.9 billion (changed N/A YoY) and the FY2025 annual result came in at -$476480.0, changed N/A from the prior year.
Non Operating Income improved to -$50080.0 in Q1 2026 per ELAB's latest filing, from -$114304.0 in the prior quarter.
Over five years, Non Operating Income peaked at $2.7 billion in Q4 2023 and troughed at -$785.6 million in Q3 2023.
A 4-year average of $423.2 million and a median of -$82192.0 in 2025 frame the typical range for Non Operating Income.
The widest YoY moves for Non Operating Income: up 140.47% in 2023, down 66.49% in 2023.
Over 4 years, Non Operating Income stood at $1.1 billion in 2022, then soared by 140.47% to $2.7 billion in 2023, then plunged by 100.0% to -$114304.0 in 2025, then surged by 56.19% to -$50080.0 in 2026.
According to Business Quant data, Non Operating Income over the past three periods registered -$50080.0, -$114304.0, and $2.7 billion for Q1 2026, Q4 2025, and Q4 2023 respectively.

#	Company	Market Cap	Enterprise Value	Gross Profit (Qtr)	Non Op. Inc. (Qtr)
1	Vertex Pharmaceuticals	139.13 Bn	131.28 Bn	2.84 Bn	-
2	Regeneron Pharmaceuticals	85.77 Bn	77.77 Bn	3.93 Bn	234.30 Mn
3	Argenx Se	64.64 Bn	59.46 Bn	1.37 Bn	-
4	Moderna	58.29 Bn	53.16 Bn	52.00 Mn	-
5	BeOne Medicines	41.92 Bn	36.82 Bn	1.53 Bn	-
6	Alnylam Pharmaceuticals	31.58 Bn	28.28 Bn	992.69 Mn	-53.64 Mn
7	BioNTech SE	28.12 Bn	9.73 Bn	668.28 Mn	-
8	Insmed	27.39 Bn	26.22 Bn	358.27 Mn	-
9	Royalty Pharma	27.27 Bn	26.43 Bn	-	-51.63 Mn
10	PMGC Holdings	31.22 Mn	12.43 Mn	385,691.00	868,237.00

Download Data